Drug Profile
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate - Gilead Sciences/Janssen R&D Ireland
Alternative Names: Complera; Edurant/Truvada; Emtricitabine/tenofovir disoproxil fumarate/rilpivirine; Emtricitabine/tenofovir disoproxil fumarate/TMC 278; Eviplera; Rilpivirine/emtricitabine/tenofovir disoproxil fumarate; Rilpivirine/Truvada; TDF/FTC/RPV; Tenofovir disoproxil fumarate/rilpivirine/emtricitabine; Truvada/Edurant™; Truvada/TMC278Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Gilead Sciences; Tibotec Pharmaceuticals
- Developer Gilead Sciences; Janssen Pharmaceutical KK; Janssen R&D Ireland; Stanford University
- Class Antiretrovirals; Deoxyribonucleosides; Nitriles; Nucleotides; Phosphonic acids; Purines; Pyrimidine nucleosides; Pyrimidines
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 31 Dec 2020 Gilead Sciences has patent protection for Emtricitabine/rilpivirine/tenofovir disoproxil fumarate in USA and European Union
- 07 Mar 2018 Gilead Sciences completes a phase III SWEAR trial for HIV-1 infections (Treatment naive) in Italy (PO) (NCT02042001)
- 12 Feb 2018 Emtricitabine/rilpivirine/tenofovir disoproxil fumarate is still in phase III SALIF trials in HIV-1 infections (second-line therapy) in Cameroon, Ghana, Kenya, Senegal, South Africa, Thailand and Uganda (NCT01709084)